TY - JOUR
T1 - Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease
T2 - A Scientific Statement From the American Heart Association
AU - Hopper, Rachel K
AU - Hansmann, Georg
AU - Hollander, Seth A
AU - Dipchand, Anne I
AU - van der Have, Oscar
AU - Iler, Colleen
AU - Herrington, Cynthia
AU - Rosenzweig, Erika B
AU - Alejos, Juan C
AU - Tran-Lundmark, Karin
AU - American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative & Resuscitation; Council on Clinical Cardiology; and Council on Cardiovascular Stroke Nursing
PY - 2024/12/9
Y1 - 2024/12/9
N2 - Children with left heart disease are at risk for developing pulmonary hypertension, initially secondary to pulmonary venous hypertension that can progress to include elevated pulmonary vascular resistance, known as combined pre- and postcapillary pulmonary hypertension. Elevated pulmonary vascular resistance may pose a risk to the right ventricle of a newly transplanted heart because of increased afterload and is an important consideration for heart transplant eligibility. However, the epidemiology, pathophysiology, optimal diagnostic and treatment approaches, and thresholds for pulmonary vascular resistance in pulmonary hypertension associated with left heart disease remain unclear because of lack of evidence, particularly in pediatrics. The result is heterogeneity with respect to hemodynamic assessment, use of pulmonary vasodilator therapies, and heart transplant listing. This scientific statement aims to synthesize the available data and highlight areas of general consensus as well as important knowledge gaps.
AB - Children with left heart disease are at risk for developing pulmonary hypertension, initially secondary to pulmonary venous hypertension that can progress to include elevated pulmonary vascular resistance, known as combined pre- and postcapillary pulmonary hypertension. Elevated pulmonary vascular resistance may pose a risk to the right ventricle of a newly transplanted heart because of increased afterload and is an important consideration for heart transplant eligibility. However, the epidemiology, pathophysiology, optimal diagnostic and treatment approaches, and thresholds for pulmonary vascular resistance in pulmonary hypertension associated with left heart disease remain unclear because of lack of evidence, particularly in pediatrics. The result is heterogeneity with respect to hemodynamic assessment, use of pulmonary vasodilator therapies, and heart transplant listing. This scientific statement aims to synthesize the available data and highlight areas of general consensus as well as important knowledge gaps.
U2 - 10.1161/HHF.0000000000000086
DO - 10.1161/HHF.0000000000000086
M3 - Review article
C2 - 39648916
SN - 1941-3297
JO - Circulation. Heart failure
JF - Circulation. Heart failure
M1 - e000086
ER -